From Yichang to the world: Sunshine Lake Pharma’s insulin enters US market
2026-05-08 20:05:08
By Zhou Chunyi.
Langlara insulin glargine injection developed by Sunshine Lake Pharma
FDA approval information published on the agency’s website
Sunshine Lake Pharma’s self-developed insulin glargine injection received approval from the US Food and Drug Administration (FDA) on May 4, becoming the first Chinese insulin product approved for the US market.
Langlara insulin glargine injection developed by Sunshine Lake Pharma
Marketed under the brand name Langlara, it is also the fourth insulin glargine product approved in the United States. The approval includes the FDA’s “interchangeable” designation, the highest standard for biosimilar drugs, allowing pharmacists to substitute it for the original branded product without requiring a new prescription.
FDA approval information published on the agency’s website
Industry analysts say the approval could help expand access to more affordable insulin options as pressure grows to lower insulin prices in the United States. As the world’s largest insulin market, the US has been long dominated by multinational pharmaceutical companies.
The insulin’s core manufacturing base is located in Yidu, Yichang, in central China’s Hubei Province.
The FDA approval marks a major milestone for high-end biopharmaceutical manufacturing in Hubei and reflects China’s growing presence in the global biopharmaceutical industry.
Since launching its insulin program in 2005, Sunshine Lake Pharma has spent nearly two decades building an integrated insulin production base in Yichang, covering active pharmaceutical ingredients, formulations, and injection devices. Its production facilities have been certified under China’s GMP standards, as well as by the FDA and the European Medicines Agency (EMA).
Backed by Yichang’s manufacturing capabilities, the company has accelerated its overseas expansion in recent years. In addition to the United States, its insulin products have already been approved in several countries and regions across the Middle East and Africa, with further global expansion underway.
The insulin’s core manufacturing base is located in Yidu, Yichang, in central China’s Hubei Province.
The FDA approval marks a major milestone for high-end biopharmaceutical manufacturing in Hubei and reflects China’s growing presence in the global biopharmaceutical industry.
Since launching its insulin program in 2005, Sunshine Lake Pharma has spent nearly two decades building an integrated insulin production base in Yichang, covering active pharmaceutical ingredients, formulations, and injection devices. Its production facilities have been certified under China’s GMP standards, as well as by the FDA and the European Medicines Agency (EMA).
Backed by Yichang’s manufacturing capabilities, the company has accelerated its overseas expansion in recent years. In addition to the United States, its insulin products have already been approved in several countries and regions across the Middle East and Africa, with further global expansion underway.
